Regulatory & Reimbursement
FDA Output, June 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in June 2026. Updated June 18.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
Stryker Signals Cardiovascular Commitment With AVS Acquisition
AVS’ intravascular lithotripsy technology gives Stryker another peripheral vascular technology to complement the Inari venous thromboembolism business it acquired in 2025.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways Pick of the Week: Happy EUDAMED Day
The first EUDAMED registration requirements took effect on May 28. Excerpted from Pathways’ Picks May 27: EU Milestones, Medtech Pilot Programs, FDA Biocomp Recognition.